INVO Fertility Q4 2025 Earnings Results & Report

INVO Fertility EPS Results

• Actual EPS: $4.18
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

INVO Fertility Revenue Results

• Actual Revenue: $1.60 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

INVO Fertility (NASDAQ:IVF). (NASDAQ: IVF) is a fertility-care company focused on expanding access to in vitro fertilization (IVF) through its INVO Procedure and related medical technology. The company develops, manufactures and commercializes INVOcell, an FDA-cleared medical device designed to provide a controlled environment for fertilizing and incubating embryos inside a woman’s body, as an alternative to conventional laboratory-based embryo culture.

The INVO Procedure uses INVOcell as part of an assisted-reproductive treatment process that can be offered by fertility specialists and clinics. INVO Fertility also supports the development and operation of fertility centers, including clinics using its technology, with the goal of providing more accessible and potentially lower-cost fertility services.

The company was formerly known as INVO Bioscience and adopted the INVO Fertility name as its business expanded from medical-device development toward a broader fertility-services model. Its activities have included commercial and clinical efforts in the United States and international markets through partnerships, distributors and fertility-center operations. The company’s offerings are intended for patients and providers seeking alternatives to traditional IVF laboratory infrastructure.